Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06109181 | Gene Therapy for ACM Due to a PKP2 Pathogenic Variant | PHASE1 | ACTIVE NOT_RECRUITING | 10 | — | — | Feb 29, 2024 | Mar 1, 2027 | Nov 12, 2025 | 5 | United States |
Evaluation of Safety and Tolerability of LX2020
| Arm | Type | Description |
|---|---|---|
| LX2020 | EXPERIMENTAL | Single ascending dose of LX2020, with a starting dose of 2.0 x10\^13 gc/kg, in multiple cohorts |
| Name | Type | Description |
|---|---|---|
| LX2020 | GENETIC | LX2020 is an adeno-associated viral vector encoding the human Plakophilin-2 (PKP2) gene (AAVrh.10hPKP2) |
Selected Inclusion Criteria: * Adults with a clinical diagnosis of ACM meeting the 2010 revised Task Force Criteria (TFC) * Genetic testing documenting a pathogenic or likely pathogenic variant in PKP2 * Frequent premature ventricular complexes (PVCs) * Implantable cardioverter-defibrillator (ICD) ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Lexeo Therapeutics, Inc. | LXEO | 3 | PHASE1 | LX2020 |